Last reviewed · How we verify
NCT01574222: VTNSCLC
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
Phase 1 trial testing autologous dendritic cell adenovirus CCL21 vaccine in Non-Small Cell Lung Cancer (NSCLC) in 1 participant. Terminated before completion.
1 March 2017
Quick facts
| Lead sponsor | VA Office of Research and Development |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 1 October 2011 |
| Primary completion | 1 March 2017 |
| Estimated completion | 1 March 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- autologous dendritic cell adenovirus CCL21 vaccine
Conditions studied
- Non-Small Cell Lung Cancer (NSCLC) — all drugs for Non-Small Cell Lung Cancer (NSCLC) →
Sponsor
VA Office of Research and Development — full company profile →
Who can join
21 and older, any sex, with Non-Small Cell Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Dendritic cell biology and its role in tumor immunotherapy.
Wang Y, Xiang Y, Xin VW, Wang XW, et al · · 2020 · cited 324× · PMID 32746880 · DOI 10.1186/s13045-020-00939-6 -
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.
Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, et al · · 2016 · cited 288× · PMID 27752258 · DOI 10.3389/fimmu.2016.00407 -
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3 -
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?
Colbeck EJ, Ager A, Gallimore A, Jones GW. · · 2017 · cited 198× · PMID 29312327 · DOI 10.3389/fimmu.2017.01830 -
Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell Infiltration.
Lee JM, Lee MH, Garon E, Goldman JW, et al · · 2017 · cited 190× · PMID 28468947 · DOI 10.1158/1078-0432.ccr-16-2821 -
Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy.
Lan T, Chen L, Wei X. · · 2021 · cited 160× · PMID 33429846 · DOI 10.3390/cells10010100 -
Molecular pathways and therapeutic targets in lung cancer.
Shtivelman E, Hensing T, Simon GR, Dennis PA, et al · · 2014 · cited 150× · PMID 24722523 · DOI 10.18632/oncotarget.1891 -
Trial watch: Dendritic cell-based interventions for cancer therapy.
Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, et al · · 2012 · cited 133× · PMID 23170259 · DOI 10.4161/onci.21494
Verify or expand the search:
- PubMed search for NCT01574222
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Small Cell Lung Cancer (NSCLC)
Currently open trials in the same condition.
- NCT07361510 — A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced No · Phase 3 · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT06710132 — Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) · Phase 1, PHASE2 · recruiting
- NCT06558799 — LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic · Phase 2 · active not recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
- NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care · Phase 1 · not yet recruiting
- NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran · NA · not yet recruiting
- NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness · NA · not yet recruiting
- NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans · NA · not yet recruiting
- NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01574222 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
- Last refreshed: 18 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01574222.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing